These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31013173)

  • 1. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
    Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
    Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    Wang JN; Zhang Y; Huang CY; Li K; Yu XB
    BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
    Tieger MG; Eliott D; Cakir B; Dahrouj M
    Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 5. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
    Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
    Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
    [No Abstract]   [Full Text] [Related]  

  • 6. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Inflammation Induced by Immune Checkpoint Inhibitors.
    Chaudot F; Sève P; Rousseau A; Maria ATJ; Fournie P; Lozach P; Keraen J; Servant M; Muller R; Gramont B; Touhami S; Mahmoud H; Quintart PA; Dalle S; Lambotte O; Kodjikian L; Jamilloux Y
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
    Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
    Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab.
    Huang Y; Khan F; Saraiya NV; Punjabi OS; Gulati V; Erickson AR; Yeh S
    J Immunother; 2023 Oct; 46(8):295-298. PubMed ID: 37315200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
    Czichos C; Wawrzynów B; Chamalis C; von Jagow B
    Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
    [No Abstract]   [Full Text] [Related]  

  • 13. SEVERE MULTIFOCAL PLACOID CHORIORETINITIS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY.
    Yu JJ; Everett L; Sassalos TM; Johnson MW
    Retin Cases Brief Rep; 2024 Jul; 18(4):459-463. PubMed ID: 36913672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
    Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
    Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
    Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
    Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
    Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
    Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population.
    Qian Y; Eppley S; Baer D; Melles RB
    Ocul Immunol Inflamm; 2024 Jan; 32(1):98-104. PubMed ID: 36637986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
    Kikuchi R; Kawagoe T; Hotta K
    BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
    Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
    Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.